Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17N4OS.Cl |
Molecular Weight | 300.808 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CC1=C(CCO)SC=[N+]1CC2=C(N)N=C(C)N=C2
InChI
InChIKey=MYVIATVLJGTBFV-UHFFFAOYSA-M
InChI=1S/C12H17N4OS.ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C12H16N4OS |
Molecular Weight | 264.347 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine
pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7120152
Curator's Comment: The transport of thiamine across the blood brain barrier was shown in rats.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9H3S4 Gene ID: 27010.0 Gene Symbol: TPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 |
|||
Target ID: GO:0005975 |
|||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | M.V.I.-12 Approved UseM.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
39 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
95 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
113 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
386 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
397 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
214 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
177 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
623 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
612 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2046 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2059 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Evaluation of vitamin and immune status of patients with chronic palatal tonsillitis]. | 2001 |
|
Effects of vitamins on hepatic nuclear binding of L-tryptophan. | 2001 |
|
Influence of a probiotic yoghurt on the status of vitamins B(1), B(2) and B(6) in the healthy adult human. | 2001 |
|
Rapid diagnosis of alcoholic ketoacidosis by proton NMR. | 2001 Apr |
|
Do breastfed infants need supplemental vitamins? | 2001 Apr |
|
Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. | 2001 Apr |
|
Nutritional evaluation of ethanol-extracted lentil flours. | 2001 Apr |
|
Analysis of slc19a2, on 1q23.3 encoding a thiamine transporter as a candidate gene for type 2 diabetes mellitus in pima indians. | 2001 Apr |
|
Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. | 2001 Apr |
|
[Chronic alcohol abuse. Benfotiamine in alcohol damage is a must]. | 2001 Apr 19 |
|
The multifaceted and widespread pathology of magnesium deficiency. | 2001 Feb |
|
Aroma extract dilution analysis of a beeflike process flavor from extruded enzyme-hydrolyzed soybean protein. | 2001 Feb |
|
Wernicke's encephalopathy following gastroplasty for morbid obesity. | 2001 Feb |
|
Evidence for non-enzymatic glycosylation in Escherichia coli. | 2001 Feb |
|
Lactic acidosis update for critical care clinicians. | 2001 Feb |
|
Consequences of a modified putative substrate-activation site on catalysis by yeast pyruvate decarboxylase. | 2001 Feb 13 |
|
Inhibitors of advanced glycation end product-associated protein cross-linking. | 2001 Feb 14 |
|
Reaction mechanism for mammalian pyruvate dehydrogenase using natural lipoyl domain substrates. | 2001 Feb 15 |
|
Cresol red thallium acetate sucrose inulin (CTSI) agar for the selective recovery of Carnobacterium spp. | 2001 Feb 28 |
|
Certification of B-group vitamins (B1, B2, B6, and B12) in four food reference materials. | 2001 Jan |
|
Molecular cloning of human thiamin pyrophosphokinase. | 2001 Jan 26 |
|
Isolation and characterization of a human thiamine pyrophosphokinase cDNA. | 2001 Jan 26 |
|
Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. | 2001 Jan-Feb |
|
Low thiamine intake and risk of cataract. | 2001 Jul |
|
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. | 2001 Jul |
|
Sulphoacetaldehyde sulpho-lyase (EC 4.4.1.12) from Desulfonispora thiosulfatigenes: purification, properties and primary sequence. | 2001 Jul 15 |
|
No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome. | 2001 Jul-Aug |
|
The crystal structure of yeast thiamin pyrophosphokinase. | 2001 Jun |
|
Sulfur compounds reduce potato toxins during extrusion cooking. | 2001 Jun |
|
Slc19a2: cloning and characterization of the murine thiamin transporter cDNA and genomic sequence, the orthologue of the human TRMA gene. | 2001 Jun |
|
Comparison of ion-pair and amide-based column reversed-phase liquid chromatography for the separation of thiamine-related compounds. | 2001 Jun 15 |
|
Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. | 2001 Jun 26 |
|
Catalytic acid-base groups in yeast pyruvate decarboxylase. 1. Site-directed mutagenesis and steady-state kinetic studies on the enzyme with the D28A, H114F, H115F, and E477Q substitutions. | 2001 Jun 26 |
|
Relationships between dietary intake and cognitive function level in Korean elderly people. | 2001 Mar |
|
[Shoshin beriberi: myth or reality?]. | 2001 Mar |
|
Simultaneous determination of thiamin and riboflavin in mushrooms by liquid chromatography. | 2001 Mar |
|
Comparison of a self-administered quantitative food amount frequency questionnaire with 4-day estimated food records. | 2001 Mar |
|
Wernicke's encephalopathy in a child: case report and MR findings. | 2001 Mar |
|
[Metabolic characteristics of the Yarrowia lipolytica strain producing alpha-ketoglutaric and citric acids from ethanol and the effect of [NH4+] and [O2] on yeast respiration and biosynthesis]. | 2001 Mar-Apr |
|
[Isolation, purification and properties of acetolactate synthase from cultured Lactococcus lactis]. | 2001 Mar-Apr |
|
The value of oral thiamine. | 2001 Mar-Apr |
|
[Other drugs administered with TPN solution]. | 2001 May |
|
[Metabolic acidosis induced by TPN]. | 2001 May |
|
[Solutions for the hyperalimentation]. | 2001 May |
|
The application of capillary electrophoresis to the analysis of vitamins in food and beverages. | 2001 May |
|
Pharmacotherapy of mental illness--a historical analysis. | 2001 May |
|
A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome. | 2001 May |
|
The bio operon on the acquired symbiosis island of Mesorhizobium sp. strain R7A includes a novel gene involved in pimeloyl-CoA synthesis. | 2001 May |
|
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
|
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA. | 2001 Sep 7 |
Patents
Sample Use Guides
The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10516094
Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:00 GMT 2025
by
admin
on
Mon Mar 31 17:47:00 GMT 2025
|
Record UNII |
X66NSO3N35
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C45812
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
WHO-VATC |
QA11DA01
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
LOINC |
2999-1
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
DSLD |
2556 (Number of products:2156)
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
LOINC |
2998-3
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
DSLD |
3328 (Number of products:50)
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
DSLD |
126 (Number of products:1158)
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
LOINC |
32554-8
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
LOINC |
20468-5
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
LOINC |
27149-4
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
LIVERTOX |
NBK548710
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
27
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
DSLD |
2241 (Number of products:66)
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
||
|
WHO-ATC |
A11DA01
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10454
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | RxNorm | ||
|
220
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
432
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
m10717
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
C874
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
59-43-8
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
X66NSO3N35
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
6042
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
26948
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
THIAMINE
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
D013831
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
2832
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
DB00152
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
SUB10969MIG
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL1547
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
DTXSID2023648
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
X66NSO3N35
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
18385
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
200-425-3
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
33283
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY | |||
|
100000092097
Created by
admin on Mon Mar 31 17:47:00 GMT 2025 , Edited by admin on Mon Mar 31 17:47:00 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|